ESMO-话题@MedSci

#ESMO#

214篇内容 | 5260人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1280995, encodeId=0a551280995d0, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=2019 ESMO|辅助到晚期一线治疗，同样需对肾细胞癌患者进行精细化的分层管理, objectType=article, longId=180453, objectId=3c7b180453c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3c7b180453c1, replyNumber=0, likeNumber=63, createdTime=2019-10-05, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3c7b180453c1, moduleTitle=2019 ESMO|辅助到晚期一线治疗，同样需对肾细胞癌患者进行精细化的分层管理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3c7b180453c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280994, encodeId=a539128099437, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=2019 ESMO|从艾氟替尼数据发布看中国抗肿瘤新药研发盛况, objectType=article, longId=180452, objectId=78f31804521c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=78f31804521c, replyNumber=0, likeNumber=59, createdTime=2019-10-05, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=78f31804521c, moduleTitle=2019 ESMO|从艾氟替尼数据发布看中国抗肿瘤新药研发盛况, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=78f31804521c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280993, encodeId=4ba8128099354, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=2019 ESMO 瑞戈非尼120 mg联合紫杉醇二线治疗晚期食管胃癌，初显疗效, objectType=article, longId=180450, objectId=c1df1804504a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c1df1804504a, replyNumber=0, likeNumber=67, createdTime=2019-10-05, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c1df1804504a, moduleTitle=2019 ESMO 瑞戈非尼120 mg联合紫杉醇二线治疗晚期食管胃癌，初显疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c1df1804504a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280992, encodeId=d299128099287, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO复盘，这些重磅研究你都知道吗？, objectType=article, longId=180418, objectId=1c381804189a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c381804189a, replyNumber=0, likeNumber=65, createdTime=2019-10-04, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c381804189a, moduleTitle=ESMO复盘，这些重磅研究你都知道吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c381804189a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280991, encodeId=d0c812809911a, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=2019 ESMO：Arfolitixorin治疗转移性结直肠癌的全球III期研究, objectType=article, longId=180370, objectId=a2be1803e048, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a2be1803e048, replyNumber=0, likeNumber=87, createdTime=2019-10-02, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a2be1803e048, moduleTitle=2019 ESMO：Arfolitixorin治疗转移性结直肠癌的全球III期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a2be1803e048)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280990, encodeId=518a128099015, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=2019 ESMO：CDK4 / 6抑制作用可提高HR + / HER2-晚期乳腺癌患者的生存率, objectType=article, longId=180364, objectId=f1771803649f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f1771803649f, replyNumber=0, likeNumber=61, createdTime=2019-10-02, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f1771803649f, moduleTitle=2019 ESMO：CDK4 / 6抑制作用可提高HR + / HER2-晚期乳腺癌患者的生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f1771803649f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280989, encodeId=49301280989cd, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=2019 ESMO临床实践指南：甲状腺癌的诊断，治疗和随访, objectType=article, longId=180330, objectId=0d8c1803306e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0d8c1803306e, replyNumber=0, likeNumber=32, createdTime=2019-10-02, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0d8c1803306e, moduleTitle=2019 ESMO临床实践指南：甲状腺癌的诊断，治疗和随访, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0d8c1803306e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280988, encodeId=1ccb1280988d8, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=2019 ESMO：罗氏的PD-L1单抗Tecentriq与VEGF单抗Avastin联合针对无法切除的肝细胞癌患者的Ib期研究中显示出令人鼓舞的结果, objectType=article, longId=180179, objectId=775a1801e9d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=775a1801e9d4, replyNumber=0, likeNumber=63, createdTime=2019-09-29, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=775a1801e9d4, moduleTitle=2019 ESMO：罗氏的PD-L1单抗Tecentriq与VEGF单抗Avastin联合针对无法切除的肝细胞癌患者的Ib期研究中显示出令人鼓舞的结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=775a1801e9d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280987, encodeId=91f8128098e57, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=2019年ESMO-GI：TAS-118联合奥沙利铂显著延长晚期胃癌患者的生存期, objectType=article, longId=175278, objectId=115d1e52785c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=115d1e52785c, replyNumber=0, likeNumber=53, createdTime=2019-07-13, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=115d1e52785c, moduleTitle=2019年ESMO-GI：TAS-118联合奥沙利铂显著延长晚期胃癌患者的生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=115d1e52785c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280986, encodeId=bfc01280986bc, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO-WCGI大会主席说：肿瘤患者的抗凝治疗不应忽视, objectType=article, longId=175118, objectId=69fd1e5118fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=69fd1e5118fd, replyNumber=0, likeNumber=71, createdTime=2019-07-12, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=69fd1e5118fd, moduleTitle=ESMO-WCGI大会主席说：肿瘤患者的抗凝治疗不应忽视, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=69fd1e5118fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280985, encodeId=f13812809850c, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=2019 ESMO胃肠癌世界大会：奥拉帕尼维持治疗改善了BRCA突变的转移性胰腺癌患者的无进展生存期, objectType=article, longId=175101, objectId=26291e5101bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=26291e5101bd, replyNumber=0, likeNumber=73, createdTime=2019-07-11, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=26291e5101bd, moduleTitle=2019 ESMO胃肠癌世界大会：奥拉帕尼维持治疗改善了BRCA突变的转移性胰腺癌患者的无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=26291e5101bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280984, encodeId=32ff128098485, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=2019年ESMO世界胃肠癌大会：灵活剂量的瑞格非尼可有效缓解其在转移性结直肠癌患者中的副作用, objectType=article, longId=175018, objectId=a1a91e501898, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a1a91e501898, replyNumber=0, likeNumber=77, createdTime=2019-07-10, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a1a91e501898, moduleTitle=2019年ESMO世界胃肠癌大会：灵活剂量的瑞格非尼可有效缓解其在转移性结直肠癌患者中的副作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a1a91e501898)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280983, encodeId=f2261280983a2, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO世界胃肠癌大会：评估脂质体伊立替康作为转移性胰腺癌一线疗法的I/II期临床研究, objectType=article, longId=174987, objectId=88ee1e49876f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=88ee1e49876f, replyNumber=0, likeNumber=66, createdTime=2019-07-09, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=88ee1e49876f, moduleTitle=ESMO世界胃肠癌大会：评估脂质体伊立替康作为转移性胰腺癌一线疗法的I/II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=88ee1e49876f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280982, encodeId=e46f1280982b4, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO世界胃肠癌大会：murlentamab的II期临床研究结果, objectType=article, longId=174985, objectId=0a901e49851b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0a901e49851b, replyNumber=0, likeNumber=91, createdTime=2019-07-09, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0a901e49851b, moduleTitle=ESMO世界胃肠癌大会：murlentamab的II期临床研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0a901e49851b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280981, encodeId=58111280981ea, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO早期乳腺癌指南发布，跟着胡夕春教授get这些HER2阳性乳腺癌的更新, objectType=article, longId=168877, objectId=2c901688e7bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c901688e7bc, replyNumber=0, likeNumber=49, createdTime=2019-06-22, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c901688e7bc, moduleTitle=ESMO早期乳腺癌指南发布，跟着胡夕春教授get这些HER2阳性乳腺癌的更新, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2c901688e7bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280980, encodeId=9d421280980a5, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=2019 ESMO临床实践指南：早期乳腺癌的诊断，治疗和随访, objectType=article, longId=167969, objectId=10be16e969c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=10be16e969c8, replyNumber=0, likeNumber=28, createdTime=2019-06-11, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=10be16e969c8, moduleTitle=2019 ESMO临床实践指南：早期乳腺癌的诊断，治疗和随访, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=10be16e969c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280979, encodeId=c4c612809e9c5, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO Breast：间歇性治疗降低晚期乳腺癌患者的治疗效果, objectType=article, longId=165497, objectId=74b916549e94, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74b916549e94, replyNumber=0, likeNumber=64, createdTime=2019-05-08, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74b916549e94, moduleTitle=ESMO Breast：间歇性治疗降低晚期乳腺癌患者的治疗效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=74b916549e94)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280978, encodeId=a90012809e816, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO Breast：三阴性乳腺癌患者的肿瘤浸润淋巴细胞水平与PD-1单抗keytruda应答率呈显著正相关, objectType=article, longId=165486, objectId=e8fc16548616, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e8fc16548616, replyNumber=0, likeNumber=113, createdTime=2019-05-08, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e8fc16548616, moduleTitle=ESMO Breast：三阴性乳腺癌患者的肿瘤浸润淋巴细胞水平与PD-1单抗keytruda应答率呈显著正相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e8fc16548616)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280977, encodeId=c18812809e7ae, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=2019 ESMO临床实践指南：肾细胞癌的诊断，治疗和随访, objectType=article, longId=161740, objectId=0907161e404f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0907161e404f, replyNumber=0, likeNumber=23, createdTime=2019-03-07, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0907161e404f, moduleTitle=2019 ESMO临床实践指南：肾细胞癌的诊断，治疗和随访, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0907161e404f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280976, encodeId=8b2d12809e69c, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=J Biomed Sci：L-caldesmon改变RANKL诱导的破骨细胞中的细胞扩散和粘附力, objectType=article, longId=159490, objectId=6d4b159490e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d4b159490e2, replyNumber=0, likeNumber=59, createdTime=2019-02-05, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d4b159490e2, moduleTitle=J Biomed Sci：L-caldesmon改变RANKL诱导的破骨细胞中的细胞扩散和粘附力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6d4b159490e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

ESMO

2020-05-29

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

2019 ESMO|辅助到晚期一线治疗，同样需对肾细胞癌患者进行精细化的分层管理

2019-10-05

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

2019 ESMO|从艾氟替尼数据发布看中国抗肿瘤新药研发盛况

2019-10-05

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

2019 ESMO 瑞戈非尼120 mg联合紫杉醇二线治疗晚期食管胃癌，初显疗效

2019-10-05

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

ESMO复盘，这些重磅研究你都知道吗？

2019-10-04

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

2019 ESMO：Arfolitixorin治疗转移性结直肠癌的全球III期研究

2019-10-02

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

2019 ESMO：CDK4 / 6抑制作用可提高HR + / HER2-晚期乳腺癌患者的生存率

2019-10-02

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

2019 ESMO临床实践指南：甲状腺癌的诊断，治疗和随访

2019-10-02

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

2019 ESMO：罗氏的PD-L1单抗Tecentriq与VEGF单抗Avastin联合针对无法切除的肝细胞癌患者的Ib期研究中显示出令人鼓舞的结果

2019-09-29

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

2019年ESMO-GI：TAS-118联合奥沙利铂显著延长晚期胃癌患者的生存期

2019-07-13

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

ESMO-WCGI大会主席说：肿瘤患者的抗凝治疗不应忽视

2019-07-12

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

2019 ESMO胃肠癌世界大会：奥拉帕尼维持治疗改善了BRCA突变的转移性胰腺癌患者的无进展生存期

2019-07-11

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

2019年ESMO世界胃肠癌大会：灵活剂量的瑞格非尼可有效缓解其在转移性结直肠癌患者中的副作用

2019-07-10

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

ESMO世界胃肠癌大会：评估脂质体伊立替康作为转移性胰腺癌一线疗法的I/II期临床研究

2019-07-09

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

ESMO世界胃肠癌大会：murlentamab的II期临床研究结果

2019-07-09

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

ESMO早期乳腺癌指南发布，跟着胡夕春教授get这些HER2阳性乳腺癌的更新

2019-06-22

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

2019 ESMO临床实践指南：早期乳腺癌的诊断，治疗和随访

2019-06-11

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

ESMO Breast：间歇性治疗降低晚期乳腺癌患者的治疗效果

2019-05-08

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

ESMO Breast：三阴性乳腺癌患者的肿瘤浸润淋巴细胞水平与PD-1单抗keytruda应答率呈显著正相关

2019-05-08

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

2019 ESMO临床实践指南：肾细胞癌的诊断，治疗和随访

2019-03-07

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

J Biomed Sci：L-caldesmon改变RANKL诱导的破骨细胞中的细胞扩散和粘附力

2019-02-05

科室
- - 订阅+
  - 更多科室
工具
服务